Back to search
Epidermolysis Bullosa, Junctional
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Epidermolysis Bullosa, Junctional trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Epidermolysis Bullosa, Junctional trials you may qualify forThis is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in…
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB…
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at great…
Herlitz junctional epidermolysis bullosa (H-JEB), an incurable, fatal, inherited skin disease, is caused by loss-of-function mutations in the LAMA3, LAMB3 or LA…
This study consists of two phases: an Observational Phase to evaluate the natural history of ocular manifestations in subjects with Dystrophic and Junctional Ep…
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
In this pilot study, APR-TD011 antimicrobial wound cleansing spray will be given to all enrolled patients with junctional EB (JEB) or dystrophic epidermolysis b…